The Cigna Group logo

The Cigna Group (CI)

Market Closed
3 Mar, 20:00
NYSE NYSE
$
283. 93
-6.92
-2.38%
After Hours
$
287. 29
+3.36 +1.18%
75.06B Market Cap
16.39 P/E Ratio
6.04% Div Yield
2,650,693 Volume
24.83 Eps
$ 290.85
Previous Close
Day Range
271.97 286.43
Year Range
239.51 350
Want to track CI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
CI earnings report is expected in 58 days (30 Apr 2026)
Cigna (CI) Lags Q4 Earnings Estimates

Cigna (CI) Lags Q4 Earnings Estimates

Cigna (CI) came out with quarterly earnings of $6.64 per share, missing the Zacks Consensus Estimate of $7.83 per share. This compares to earnings of $6.79 per share a year ago.

Zacks | 1 year ago
Cigna misses quarterly profit estimates on higher medical costs

Cigna misses quarterly profit estimates on higher medical costs

Cigna forecast annual profit below Wall Street expectations on Thursday and missed estimates for the fourth quarter, hurt by higher medical costs for a type of employer-sponsored healthcare plan.

Reuters | 1 year ago
Cigna 2024 Profits Eclipse $3 Billion Despite Rising Costs

Cigna 2024 Profits Eclipse $3 Billion Despite Rising Costs

The Cigna Group Thursday reported more than $3.4 billion in 2024 net income including $1.4 billion in the fourth quarter as the health insurer worked to overcome rising medical expenses in its employer plans.

Forbes | 1 year ago
Cigna to take steps to lower out-of-pocket costs of prescription drugs

Cigna to take steps to lower out-of-pocket costs of prescription drugs

Cigna's unit Evernorth Health said on Wednesday it will take several steps to help lower out-of-pocket cost of prescription drugs for patients at its pharmacy stores.

Reuters | 1 year ago
Rising Medical Costs to Affect Cigna Q4 Earnings? Check Estimates Here

Rising Medical Costs to Affect Cigna Q4 Earnings? Check Estimates Here

CI's fourth-quarter results are likely to have benefited from growing premiums and pharmacy revenues.

Zacks | 1 year ago
Cigna: Buy The Drop On This Undervalued Growth Stock

Cigna: Buy The Drop On This Undervalued Growth Stock

Cigna's current valuation presents a compelling opportunity, trading at a forward PE of 9.9, significantly below its historical average of 12.0x. The company carries diversified revenue streams and consistent earnings growth, with Healthcare and Evernorth divisions driving strong performance and a 13% EPS CAGR over 10 years. Management targets 10-14% long-term annual EPS growth, supported by increased biosimilar adoption, behavioral health services growth, and aggressive share buybacks.

Seekingalpha | 1 year ago
Raymond James Analysts' Best Picks Could Explode Again in 2025: 4 Red-Hot Dividend Stocks

Raymond James Analysts' Best Picks Could Explode Again in 2025: 4 Red-Hot Dividend Stocks

As the calendar turns to 2025, the leading Wall Street firms are releasing their top stock picks for the new year.

247wallst | 1 year ago
Market Madness: 3 Blue-Chip Dividend Steals You Can't Ignore

Market Madness: 3 Blue-Chip Dividend Steals You Can't Ignore

The U.S. economy added 256,000 jobs last month, far exceeding expectations, which suggests a strong economy but reduces the likelihood of further Fed rate cuts. Rising long-term rates increase borrowing costs and competition for stocks, negatively impacting rate-sensitive sectors like utilities, real estate, and consumer staples. Despite a challenging market environment, equities still offer value, particularly in high-quality blue-chip stocks.

Seekingalpha | 1 year ago
High-cost weight loss drugs are sending employers to nutrition counseling in a boost for startups

High-cost weight loss drugs are sending employers to nutrition counseling in a boost for startups

Employers are increasingly requiring workers on GLP-1 medications to enroll in nutrition and lifestyle coaching programs. Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss management program.

Cnbc | 1 year ago
Cigna Stock Plunges 18.7% in 3 Months: Should You Buy, Hold or Sell?

Cigna Stock Plunges 18.7% in 3 Months: Should You Buy, Hold or Sell?

Despite market challenges, CI's strong fundamentals and growth drivers make it worth holding for long-term investors looking to capitalize on future recovery opportunities.

Zacks | 1 year ago
How Cigna Remains at the Top of the Health Insurance Food Chain

How Cigna Remains at the Top of the Health Insurance Food Chain

The health insurance industry has received a lot of backlash over its managed care practices that bog down providers with pre-authorizations and rampant medical claim denials. The rise in medical benefits ratios (MBRs) driven by Medicare Advantage plans have squeezed margins for major health insurance providers like Humana Inc. NYSE: HUM, UnitedHealth Group Inc. NYSE: UNH, and CVS Health Co. NYSE: CVS.

Marketbeat | 1 year ago
Here's Why Cigna (CI) is a Strong Value Stock

Here's Why Cigna (CI) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
Loading...
Load More